Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 207-214

  Maretti Mira, A C ^a,c   De Oliveira Neto, M P ^b   Da Cruz, A M ^a   De Oliveira, M P ^a   Craft, N ^c   Pirmez, C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

American tegumentary leishmaniasis; Cytokines; Leishmaniasis immunology; Matrix metalloproteinases; Therapeutic failure

Indexed keywords

GAMMA INTERFERON; GELATINASE A; INTERLEUKIN 10; MEGLUMINE ANTIMONATE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

AMERICAN CUTANEOUS LEISHMANIASIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; SKIN NECROSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIMONY; ANTIPROTOZOAL AGENTS; CYTOKINES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIASIS, CUTANEOUS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; REGENERATION; SKIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT FAILURE;

EID: 78650803209     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04285.x     Document Type: Article

References (42)

1. Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989; 41:687-725.
2. Costa JML, Netto EM, Vale KC, Osaki NK, Tada MS, Marsden PD. Spontaneous healing of cutaneous Leishmania brasiliensis brasiliensis ulcers. Trans R Soc Trop Med Hyg 1987; 81:606.
3. Castes M, Agnelli A, Rondon AJ. Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis. Clin Exp Immunol 1984; 57:279-86.
4. Mendonca SC, Coutinho SG, Amendoeira RR, Marzochi MC, Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64:269-76.
5. Pirmez C, Cooper C, Paes-Oliveira M, Schubach A, Torigian VK, Modlin RL. Immunologic responsiveness in American cutaneous leishmaniasis lesions. J Immunol 1990; 145:3100-4.
6. Da Cruz AM, Bertho AL, Oliveira-Neto MP, Coutinho SG. Flow cytometric analysis of cellular infiltrate from American tegumentary leishmaniasis lesions. Br J Dermatol 2005; 153:537-43.
7. Ridley MJ, Ridley DS. Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase. Br J Exp Pathol 1984; 65:327-36.
8. Campanelli AP, Roselino AM, Cavassani KA et al. CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 2006; 193:1313-22.
9. Pirmez C. Immunopathology of American cutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1992; 87 (Suppl. 5):105-9.
10. Esterre P, Dedet JP, Frenay C, Chevallier M, Grimaud JA. Cell populations in the lesion of human cutaneous leishmaniasis: a light microscopical, immunohistochemical and ultrastructural study. Virchows Arch A Pathol Anat Histopathol 1992; 421:239-47.
11. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91:1390-5.
12. Coutinho SG, Oliveira MP, Da Cruz AM et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 1996; 84:144-55.
13. Caceres-Dittmar G, Tapia FJ, Sanchez MA et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91:500-5.
14. Mirastschijski U, Haaksma CJ, Tomasek JJ, Agren MS. Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Exp Cell Res 2004; 299:465-75.
15. Agren MS. Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds. Arch Dermatol Res 1999; 291:583-90.
16. Woessner JF Jr. The family of matrix metalloproteinases. Ann NY Acad Sci 1994; 732:11-21.
17. Makela M, Larjava H, Pirila E et al. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell Res 1999; 251:67-78.
18. Salo T, Makela M, Kylmaniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994; 70:176-82.
19. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S. Regulation of matrix metalloproteinase activity. Ann NY Acad Sci 1994; 732:31-41.
20. Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 2005; 163:157-64.
21. Seomun Y, Kim JT, Joo CK. MMP-14 mediated MMP-9 expression is involved in TGF-beta1-induced keratinocyte migration. J Cell Biochem 2008; 104:934-41.
22. Makela M, Salo T, Larjava H. MMP-9 from TNF alpha-stimulated keratinocytes binds to cell membranes and type I collagen: a cause for extended matrix degradation in inflammation? Biochem Biophys Res Commun 1998; 253:325-35.
23. Stearns ME, Wang M, Hu Y, Garcia FU, Rhim J. Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. Clin Cancer Res 2003; 9:1191-9.
24. Harris JE, Fernandez-Vilaseca M, Elkington PT, Horncastle DE, Graeber MB, Friedland JS. IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J 2007; 21:356-65.
25. Fontana VA, Sanchez M, Cebral E, Calvo JC. Interferon-gamma inhibits metalloproteinase activity and cytotrophoblast cell migration. Am J Reprod Immunol 2010; 64:20-6.
26. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101:64-8.
27. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996; 106:1119-24.
28. Costa JD, Nogueira de Melo AC, Vermelho AB, Meirelles MN, Porrozzi R. In vitro evidence for metallopeptidase participation in hepatocyte damage induced by Leishmania chagasi-infected macrophages. Acta Trop 2008; 106:175-83.
29. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 2002; 197:179-87.
30. Oliveira-Neto MP, Mattos MS, Perez MA et al. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol 2000; 39:506-14.
31. Chang YH, Lin IL, Tsay GJ et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 2008; 41:955-9.
32. Dubois B, Opdenakker G, Carton H. Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neurol Belg 1999; 99:53-6.
33. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002; 45:1011-6.
34. Mirastschijski U, Impola U, Jahkola T, Karlsmark T, Agren MS, Saarialho-Kere U. Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. Hum Pathol 2002; 33:355-64.
35. Teles RM, Teles RB, Amadeu TP et al. High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions. Infect Immun 2010; 78:1012-21.
36. Barral A, Teixeira M, Reis P et al. Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol 1995; 147:947-54.
37. Belkaid Y, Hoffmann KF, Mendez S et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-506.
38. Harms G, Zwingenberger K, Chehade AK et al. Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet 1989; 1:1287-92.
39. Sadick MD, Locksley RM, Tubbs C, Raff HV. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol 1986; 136:655-61.
40. Galboiz Y, Shapiro S, Lahat N, Miller A. Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol 2002; 131:191-200.
41. Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 2004; 172:1848-55.
42. Agren MS, Mirastschijski U, Karlsmark T, Saarialho-Kere UK. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 2001; 10:337-48.